Intellia Therapeutics (NTLA) Competitors $7.36 -0.14 (-1.87%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.34 -0.03 (-0.34%) As of 04/15/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. PTGX, CPRX, MRUS, ALVO, SRRK, CRNX, APLS, ACAD, IMVT, and VKTXShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), ACADIA Pharmaceuticals (ACAD), Immunovant (IMVT), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Protagonist Therapeutics Catalyst Pharmaceuticals Merus Alvotech Scholar Rock Crinetics Pharmaceuticals Apellis Pharmaceuticals ACADIA Pharmaceuticals Immunovant Viking Therapeutics Intellia Therapeutics (NASDAQ:NTLA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Does the media prefer NTLA or PTGX? In the previous week, Intellia Therapeutics had 30 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 41 mentions for Intellia Therapeutics and 11 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.41 beat Intellia Therapeutics' score of 0.17 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 6 Very Positive mention(s) 6 Positive mention(s) 24 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Protagonist Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, NTLA or PTGX? Protagonist Therapeutics has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M13.16-$481.19M-$5.25-1.40Protagonist Therapeutics$434.43M6.63-$78.96M$4.2011.18 Do analysts recommend NTLA or PTGX? Intellia Therapeutics currently has a consensus target price of $37.56, suggesting a potential upside of 410.27%. Protagonist Therapeutics has a consensus target price of $65.44, suggesting a potential upside of 39.39%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer NTLA or PTGX? Intellia Therapeutics received 152 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 68.90% of users gave Intellia Therapeutics an outperform vote while only 61.65% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44368.90% Underperform Votes20031.10% Protagonist TherapeuticsOutperform Votes29161.65% Underperform Votes18138.35% Do institutionals & insiders have more ownership in NTLA or PTGX? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 3.2% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NTLA or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Intellia Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 34.68% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Protagonist Therapeutics 52.76%34.68%30.98% Which has more volatility and risk, NTLA or PTGX? Intellia Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. SummaryProtagonist Therapeutics beats Intellia Therapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$761.89M$2.32B$5.33B$7.57BDividend YieldN/A0.78%5.11%4.32%P/E Ratio-1.356.1121.7317.81Price / Sales13.1647.32379.2094.61Price / CashN/A15.7538.1534.64Price / Book0.632.956.464.00Net Income-$481.19M-$65.73M$3.20B$247.23M7 Day Performance3.95%4.76%2.85%1.45%1 Month Performance-19.47%-14.92%-8.55%-6.24%1 Year Performance-66.25%-18.39%10.46%0.60% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.3268 of 5 stars$7.36-1.9%$37.56+410.3%-67.9%$761.89M$57.88M-1.35600Gap DownPTGXProtagonist Therapeutics3.8055 of 5 stars$43.55-2.0%$62.56+43.6%+76.6%$2.68B$434.43M16.39120Positive NewsCPRXCatalyst Pharmaceuticals4.6031 of 5 stars$21.66-6.1%$32.29+49.1%+50.9%$2.64B$491.73M18.4380Positive NewsGap DownMRUSMerus2.8298 of 5 stars$37.06-2.7%$85.31+130.2%+4.7%$2.55B$36.13M-9.3637Positive NewsALVOAlvotech1.7014 of 5 stars$8.27-2.7%$18.00+117.7%-31.2%$2.49B$489.68M-4.471,026Analyst RevisionGap DownSRRKScholar Rock3.8738 of 5 stars$26.19-2.6%$42.67+62.9%+126.7%$2.48B$33.19M-11.16140Positive NewsCRNXCrinetics Pharmaceuticals3.6081 of 5 stars$26.21-2.5%$73.00+178.6%-32.1%$2.44B$1.04M-7.04210Positive NewsAPLSApellis Pharmaceuticals4.1187 of 5 stars$19.59-1.9%$45.59+132.7%-63.2%$2.43B$781.37M-9.55770Gap DownACADACADIA Pharmaceuticals4.0133 of 5 stars$14.58-5.2%$23.93+64.1%-11.2%$2.43B$957.80M18.70510Analyst RevisionNews CoverageIMVTImmunovant2.3815 of 5 stars$14.15-2.9%$41.00+189.7%-49.2%$2.40BN/A-5.40120Short Interest ↑Positive NewsVKTXViking Therapeutics4.2748 of 5 stars$21.16-6.5%$95.18+349.9%-65.5%$2.38BN/A-21.2520Options VolumeNews Coverage Remove Ads Related Companies and Tools Related Companies Protagonist Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Merus Alternatives Alvotech Alternatives Scholar Rock Alternatives Crinetics Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives Immunovant Alternatives Viking Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
